Hormonal
Insulin resistance is a multisystem disorder that predisposes individuals to both cardiovascular disease and type 2 diabetes, often manifesting as the metabolic syndrome (abdominal obesity, atherogenic dyslipidemia, hypertension, glucose intolerance, and prothrombotic state).
If you have high blood pressure, high cholesterol, and high blood sugar, you likely have insulin resistance. This cluster of conditions, called the metabolic syndrome, significantly increases your heart disease risk. The most effective strategy is to address the root cause: improve your insulin sensitivity through weight loss, physical activity, and dietary changes, rather than just managing each number in isolation.
Research suggests that insulin resistance is a multisystem disorder that induces multiple metabolic alterations... Patients with insulin resistance often have abdominal obesity. Metabolic risk factors that occur commonly in patients with insulin resistance are atherogenic dyslipidemia, hypertension, glucose intolerance, and a prothrombotic state.
Why this rating
Supported by prospective studies and the definition of the metabolic syndrome by the AHA.
Source
Diabetes and Cardiovascular Disease
Scott M. Grundy et al. · Circulation · 1999
DOI 10.1161/01.cir.100.10.1134
More from this paper
- Diabetes mellitus is an independent major risk factor for cardiovascular disease (CVD), and from a cardiovascular medicine perspective, it is appropriate to classify diabetes itself as a cardiovascular disease.Strong
- Aggressive LDL-lowering therapy reduces recurrent coronary heart disease (CHD) events in patients with diabetes, even if their baseline LDL cholesterol is not markedly elevated.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →